

6360

Attorney Docket No.: 6236.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knudsen

Serial No.: 10/003,846

Filed: December 4, 2001

Confirmation No.: 6436



Group Art Unit: To be assigned

Examiner: To be assigned

For: Method of Identifying Compounds Capable of Acting as Agonists or Antagonists of G-Protein Coupled Receptors

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on February 27, 2002.

Carol McFarlane-Fishberg _____
(name of person mailing paper)
(signature of person mailing paper)

23650

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knudsen et al.

Application No.: 10/003,846

Filed: December 4, 2001

MAR 6 7 2002

F Group

Art Unit: To be assigned

Examiner: To be assigned

Confirmation No.: 6436

For: Method of Identifying Compounds Capable of Acting as Agonists or Antagonists of G-Protein Coupled Receptors

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 98/55635;
2. WO 99/55356;


3. WO 01/67106 A2;
4. U.S. Patent 5,891,646;
5. U.S. Patent 6,110,693; and
6. U.S. Patent 6,242,205 B1.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application. Therefore, no fee is due.

Respectfully submitted,

Date: February 27, 2002



Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.